Quantum-Si incorporated operates the first next-generation protein sequencing platform for the healthcare industries.
| Revenue (TTM) | $1.85M |
| Gross Profit (TTM) | 741,000 |
| EBITDA | $-91.23M |
| Operating Margin | -9323.00% |
| Return on Equity | -46.40% |
| Return on Assets | -24.80% |
| Revenue/Share (TTM) | $0.01 |
| Book Value | $0.92 |
| Price-to-Book | 0.85 |
| Price-to-Sales (TTM) | 89.43 |
| EV/Revenue | 25.32 |
| EV/EBITDA | 0.63 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | -69.40% |
| Shares Outstanding | $197.82M |
| Float | $179.19M |
| % Insiders | 10.51% |
| % Institutions | 29.88% |
Volatility is currently contracting
BRANFORD, Conn., July 27, 2026 (GLOBE NEWSWIRE) -- Quantum-Si Incorporated (Nasdaq: QSI) (“Quantum-Si,” “QSI” or the “Company”), a proteomics technology company redefining protein analysis through single-molecule detection, today announced that it will report financial results for the second quarter 2026 on Thursday, August 13, 2026.
BRANFORD, Conn.--(BUSINESS WIRE)--Quantum-Si and Cell Signaling Technology Partner to Advance Post-Translational Modification Analysis on Proteus™.
BRANFORD, Conn.--(BUSINESS WIRE)--Quantum-Si Announces the Expansion of the Proteus™ Roadshow.
Quantum-Si incorporated (QSI) Shareholder/Analyst Call Prepared Remarks Transcript
BRANFORD, Conn.--(BUSINESS WIRE)--Quantum-Si Reports First Quarter 2026 Financial Results and Highlights Proteus™ Development Milestones.
BRANFORD, Conn.--(BUSINESS WIRE)--Quantum-Si to Participate in the H.C. Wainwright 4th Annual BioConnect Investor Conference.
BRANFORD, Conn.--(BUSINESS WIRE)--Quantum-Si Announces Successful Sequencing on Integrated Proteus™ Instruments.
BRANFORD, Conn.--(BUSINESS WIRE)--Quantum-Si Announces First Customer Samples Tested on the Proteus™ Prototype System.
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on QSI and any ticker you trade — then tracks every position and per-strategy win rate.
